Telix swings to H1 FY26 net profit of US$38 million; revenue rises 22% to US$477 million
Reuters2026/08/19 23:10- Telix Pharmaceuticals reported H1 2026 revenue of US$477 million, up 22% year over year.
- Net profit swung to US$38 million; operating profit climbed to US$46 million.
- Adjusted EBITDA (non-IFRS) more than doubled to US$52 million, while cash balance rose 78% to US$252 million.
- R&D spending increased 51% to US$124 million; other income included a US$40 million upfront payment from Regeneron.
- FY 2026 revenue guidance stayed at US$950 million-US$970 million, with revenue expected at the upper end of the range.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
IBM (IBM.US) Quantum Computing Reaches Key Milestone: Successfully Connects and Cools Two Cryogenic Modules, Aiming to Launch the World's First Fault-Tolerant Quantum Computer by 2029
On Wednesday, IBM announced that it has successfully connected and cooled two cryogenic modules within the same operating environment, and has completed preliminary testing. The company stated that this modular architecture is designed to scale into an ultra-low temperature shared system capable of connecting hundreds of quantum chips, marking a key step toward the launch of IBM Quantum Starling in 2029.
AF2 Capital plans 5.33-for-1 share consolidation effective Aug. 20
Camp4 Therapeutics CSO Daniel Tardiff disposes of 1,738 common shares worth $8,272.88
Crypto prices
More
